Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03458897 · ClinicalTrials.gov registry record · NA

Quantitative MRI for Patients With Sickle Cell Disease Undergoing Hematopoietic Cell Transplant

A NA study of Sickle Cell Disease, sponsored by University of Michigan.

Completed
Registry status
NA
Development phase
7
Enrollment target
1
Study location

NCT03458897: Completed NA study of Sickle Cell Disease, sponsored by University of Michigan.

NCT03458897 is a NA study of Sickle Cell Disease that has completed, run by University of Michigan. The registered enrollment target is 7 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03458897, a NA study of Sickle Cell Disease, has completed, sponsored by University of Michigan.

COMPLETED
Registry status
NA
Development phase
7 participants
Enrollment target
1
Study location

Study Summary

The primary purpose of this research is to determine if it is feasible to perform serial magnetic resonance imaging (MRI) to evaluate the amount of bone marrow cells (also called cellularity) and iron stores before and after bone marrow transplantation for severe sickle cell disease.

Primary Outcome

Feasibility will be measured by the number of subjects who undergo at least 2 of 4 scheduled functional MRI's

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST serial functional magnetic resonance imaging (MRI)

Study Locations (1)

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2018-05-03
Est. Completion 2020-09-01
Phase NA
University of Michigan

1,327 total trials

What the finished NCT03458897 record still lists

NCT03458897 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which serial functional magnetic resonance imaging (MRI) is the first listed.

NCT03458897 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT03458897 about?

NCT03458897 is a clinical study titled "Quantitative MRI for Patients With Sickle Cell Disease Undergoing Hematopoietic Cell Transplant". The primary purpose of this research is to determine if it is feasible to perform serial magnetic resonance imaging (MRI) to evaluate the amount of bone marrow cells (also called cellularity) and iron stores before and after bone marrow transplantation for severe sickle cell disease.

What is the current status of trial NCT03458897?

This trial is currently completed. It is a NA study. The enrollment target is 7 participants. The study started on 2018-05-03. Estimated completion is 2020-09-01.

What conditions does trial NCT03458897 study?

This clinical trial studies the following conditions: Sickle Cell Disease.

What interventions are being tested in trial NCT03458897?

The interventions under investigation include: serial functional magnetic resonance imaging (MRI) (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT03458897?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03458897 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sickle Cell Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03458897's enrollment target sits among peer trials

7 202nd of 213 higher than 10 of 213 other Sickle Cell Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03458897, the US trial registry maintained by the National Library of Medicine. NCT03458897 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.